Your browser doesn't support javascript.
loading
1H-Pyrrolo[3,2-b]pyridine GluN2B-Selective Negative Allosteric Modulators.
Chrovian, Christa C; Soyode-Johnson, Akinola; Wall, Jessica L; Rech, Jason C; Schoellerman, Jeff; Lord, Brian; Coe, Kevin J; Carruthers, Nicholas I; Nguyen, Leslie; Jiang, Xiaohui; Koudriakova, Tatiana; Balana, Bartosz; Letavic, Michael A.
Afiliação
  • Chrovian CC; Janssen Research & Development, LLC, 3210 Merryfield Row, San Diego, California 92121-1126, United States.
  • Soyode-Johnson A; Janssen Research & Development, LLC, 3210 Merryfield Row, San Diego, California 92121-1126, United States.
  • Wall JL; Janssen Research & Development, LLC, 3210 Merryfield Row, San Diego, California 92121-1126, United States.
  • Rech JC; Janssen Research & Development, LLC, 3210 Merryfield Row, San Diego, California 92121-1126, United States.
  • Schoellerman J; Janssen Research & Development, LLC, 3210 Merryfield Row, San Diego, California 92121-1126, United States.
  • Lord B; Janssen Research & Development, LLC, 3210 Merryfield Row, San Diego, California 92121-1126, United States.
  • Coe KJ; Janssen Research & Development, LLC, 3210 Merryfield Row, San Diego, California 92121-1126, United States.
  • Carruthers NI; Janssen Research & Development, LLC, 3210 Merryfield Row, San Diego, California 92121-1126, United States.
  • Nguyen L; Janssen Research & Development, LLC, 3210 Merryfield Row, San Diego, California 92121-1126, United States.
  • Jiang X; Janssen Research & Development, LLC, 3210 Merryfield Row, San Diego, California 92121-1126, United States.
  • Koudriakova T; Janssen Research & Development, LLC, 3210 Merryfield Row, San Diego, California 92121-1126, United States.
  • Balana B; Janssen Research & Development, LLC, 3210 Merryfield Row, San Diego, California 92121-1126, United States.
  • Letavic MA; Janssen Research & Development, LLC, 3210 Merryfield Row, San Diego, California 92121-1126, United States.
ACS Med Chem Lett ; 10(3): 261-266, 2019 Mar 14.
Article em En | MEDLINE | ID: mdl-30891123
ABSTRACT
Herein, we disclose a series of selective GluN2B negative allosteric modulators containing a 1H-pyrrolo[3,2-b]pyridine core. Lead optimization efforts included increasing brain penetration as well as decreasing cytochrome P450 inhibition and hERG channel binding. The series was also optimized to reduce metabolic turnover in human and rat. Compounds 9, 25, 30, and 34 have good in vitro GluN2B potency and good predicted absorption, but moderate to high projected clearance. They were assessed in vivo to determine their target engagement. All four compounds achieved >75% receptor occupancy after an oral dose of 10 mg/kg in rat. Compound 9 receptor occupancy was measured in a dose-response experiment, and its ED50 was found to be 2.0 mg/kg.

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2019 Tipo de documento: Article